Skip to main content
Fig. 6 | Diabetology & Metabolic Syndrome

Fig. 6

From: Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Fig. 6

Modulatory effects of dapagliflozin on the myocardial AMPK/mTOR signaling pathway and autophagic flux in T2DM rats. a Representative western blot bands of p-AMPK and p-mTOR levels in the myocardium. b, c Densitometric semi-quantitative determination of protein expression. d Representative western blot bands of myocardial p62 and LC3-I/II expression. e, f Semi-quantitative analysis of relative protein levels. Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01 vs. Lean; #P < 0.05, ##P < 0.01 vs. ZDF

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us